Immune checkpoint inhibitors plus neoadjuvant chemotherapy in early triple-negative breast cancer: a systematic review and meta-analysis
Abstract Purpose Some studies have shown that Immune checkpoint inhibitors (ICIs) have a favorable efficacy in advanced triple negative breast cancer (TNBC) patients, but the results are controversial in neoadjuvant chemotherapy (NACT) stage. The purpose of this study is to evaluate the efficacy and...
Enregistré dans:
Auteurs principaux: | Yuanfang Xin, Guoshuang Shen, Yonghui Zheng, Yumei Guan, Xingfa Huo, Jinming Li, Dengfeng Ren, Fuxing Zhao, Zhen Liu, Zitao Li, Jiuda Zhao |
---|---|
Format: | article |
Langue: | EN |
Publié: |
BMC
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/7e5c3c4c18ff45ae9e8fc223d09d5bf1 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Triple-Negative Breast Cancer: Assessing the Role of Immunohistochemical Biomarkers on Neoadjuvant Treatment
par: da Silva JL, et autres
Publié: (2021) -
Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial)
par: Nieves Martinez Chanza, et autres
Publié: (2021) -
Efficacy and Safety of Adding Immune Checkpoint Inhibitors to Neoadjuvant Chemotherapy Against Triple-Negative Breast Cancer: A Meta-Analysis of Randomized Controlled Trials
par: Yunhai Li, et autres
Publié: (2021) -
A Combined Nomogram Model to Predict Disease-free Survival in Triple-Negative Breast Cancer Patients With Neoadjuvant Chemotherapy
par: Bingqing Xia, et autres
Publié: (2021) -
Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious Diseases
par: Xin Cai, et autres
Publié: (2021)